Shares of Medpace Hldgs MEDP were flat in after-market trading after the company reported Q2 results.
Quarterly Results
Earnings per share rose 65.62% year over year to $1.06, which beat the estimate of $0.99.
Revenue of $278,293,000 up by 35.76% year over year, which beat the estimate of $272,100,000.
Guidance
Earnings guidance hasn't been issued by the company for now.
Medpace Hldgs hasn't issued any revenue guidance for the time being.
Price Action
Company's 52-week high was at $196.12
52-week low: $105.36
Price action over last quarter: Up 8.82%
Company Overview
Medpace Holdings Inc is a clinical contract research organization. It is engaged in scientifically-driven outsourced clinical development services to the biotechnology, pharmaceutical, and medical device industries. It operates in North America, Europe, Africa, Middle East, Asia-Pacific and Latin America.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.